Cognilum
Phase 1- Indications
- Autism Spectrum Disorder
Company intelligence / Profile preview
JelikaLite has developed "Cognilum," a home-based wearable LED device for children with autism that delivers non-invasive transcranial photobiomodulation. The system integrates real-time sensors and an AI-driven feedback loop to personalize treatment. Results from double-blind and open-label clinical studies have shown improvements in responsiveness, speech, and social interaction in autistic children. The product has received FDA Breakthrough Device Designation but is not yet commercially available. A recent peer-reviewed publication details positive outcomes from their open-label study in children aged 2–7 years old with ASD.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on JelikaLite.